Kornimate/medical-research-clean huggingface dataset:
the novel 18f-labeled mao-b pet tracer study in parkinsonism patients

Conditions: Parkinson Disease

Summary: this study mainly aims to prospectively evaluate the changes of reactive astrogliosis in parkinsonism patients of chinese population by the novel 18f-labeled mao-b pet tracer.

18f-smbt-1, the novel 18f-labeled mao-b pet tracer, was evaluated reactive astrogliosis in alzheimer's disease successfully. in this prospective study, we assess the changes of reactive astrocytes in cerebral gray matter and white matter on parkinson's disease by 18f-smbt-1 pet/ct imaging among chinese population.

Eligibility criteria:
inclusion criteria: * aged from 40 to 90 years old. * clinically diagnosed as parkinsonism, including parkinson's disease and atypical parkinsonism syndromes. * can cooperate with 18f-fdg pet/ct, 18f-fp-cit pet/ct and 3d t1-weighted structural mr scans. * complete clinical data, including modified hoehn and yahr staging scale and the movement disorders society unified parkinson's disease rating scale (mds-updrs). exclusion criteria: * cannot cooperate with pet/ct or mr examination. * associated with brain diseases such as stroke, brain trauma, brain tumor, and cranial surgery.

Keywords: pet/ct
low intensity aerobic exercise and active exercises in cancer patients receiving palliative care

Conditions: Cancer

Summary: to compare the effect of low intensity aerobic exercise and active rom exercises on cancer related fatigue and its associated symptoms and quality of life in cancer patients receiving palliative care.


Eligibility criteria:
inclusion criteria: * ability to give written consent. * diagnosed advance cancer specifically gastrointestinal tract (git) cancer, lung cancer and breast cancer etc. (stage 2 and 3). * intensity of fatigue ≥4 out of 10 on fatigue numerical rating scale in first visit observation * survival expectancy more than one month, * functional status allowing the participants to participate in the proposed therapy. exclusion criteria: * anemia (hb ≤ 8g/dl), * existence of other comorbidities causing fatigue (i.e. parkinson's, multiple sclerosis, heart failure), * infection requiring antibodies * bone metastases, * thrombocytopenia (\<50×109/l), * myocardial infarction within the past three months * uncontrolled hypertension (diastolic pressure \>95 mm hg).

Keywords: low intensity aerobic exercise rom exercise palliative care
usability of zubsolv sublingual tablets 5.7/1.4 to suboxone sublingual film 8/2 in buprenorphine/naloxone treated opioid dependent population

Conditions: Opioid Dependence

Summary: the primary objective of this study is to compare overall patient preference for either suboxone® sublingual film 8/2 or zubsolv® sublingual tablets 5.7/1.4. suboxone sublingual film 8/2 contains 8mg buprenorphine and 2mg naloxone. zubsolv sublingual tablets contain 5.7 mg buprenorphine and 1.4 mg naloxone. both interventions act as a substitute for opiate drugs like heroin, morphine or oxycodone and help withdrawal from opiate drugs over a period of time.


Eligibility criteria:
inclusion criteria: * currently on a single daily dose of 8/2 of suboxone or generic equivalent, or 5.7/1.4 mg zubsolv for treatment of opioid dependence that has been medically confirmed. * in good general health with no specific contraindication for treatment with buprenorphine or naloxone. * the ability to understand, sign and date written consent and health information portability and accountability act (hipaa) authorization forms, which must be obtained prior to any study related procedures being completed. * female subjects must be postmenopausal for at least 2 years, surgically sterile (i.e. tubal ligation, hysterectomy, or bilateral ovariectomy), or practicing an effective method of contraception during the study with one of the following methods: oral contraception, intrauterine device (iud), abstinence, contraceptive injections, conscientious use of a diaphragm or condoms and spermicidal foam, systemic (implant) contraception or partner has had a vasectomy. exclusion criteria: * subject is taking other opioids (other than buprenorphine/naloxone) that may interfere with the study evaluations or compromise the safety of the subject. * subject is not able to read or have other impairments that may prevent completion of questionnaires or other study evaluations * subject has open sores present in the oral cavity. * subject has participated in any previous clinical testing involving investigational drug within the 4 weeks prior to study start. * subject is pregnant, lactating or planning a pregnancy * subject is currently participating in any other type of clinical testing. * subject has a medical condition that in the investigator's opinion could affect the taste assessments required by the study * subject is judged by the investigator after reviewing medical history to be unsuitable for any other reason that may either place the subject at increased risk during participation or interfere with the interpretation of the study outcomes.

Keywords: opioid dependence buprenorphine/naloxone opioid-related disorders
imfinzi study in patients with extensive stage small cell lung cancer

Conditions: Carcinoma, Small Cell

Summary: to capture safety(fn) when imf is administered to patients with extensive stage small cell lung cancer in clinical practice after launch

to capture the onset (incidence, severity, intervention, outcome, and others) of febrile neutropenia in patients with extensive stage small cell lung cancer who receive durvalumab in combination with platinum agent and etoposide under the actual use.

Eligibility criteria:
inclusion criteria: -patients with extensive stage small cell lung cancer who are receiving the product in combination with platinum agent and etoposide. exclusion criteria: -patients who have no treatment history with the product (i.e.,durvalumab)
comparison of progestin primed ovarian stimulation (ppos) vs.gnrh antagonist methods on ivf outcomes

Conditions: IVF; Fertility Issues; Infertility

Summary: the goal of this randomized clinical trial is to compare the effects of two different ovarian stimulation methods: progestin primed ovarian stimulation (ppos) vs. gnrh antagonist in embryologic outcomes of ivf patients.

the goal of this randomized clinical trial is to compare the effects of two different ovarian stimulation methods: progestin primed ovarian stimulation (ppos) vs. gnrh antagonist in embryologic outcomes of ivf patients. ovarian stimulation will be conducted according to the assigned arm protocol. both artificially prepared and modified natural cycles will be eligible to be included and the choice will be done according to the doctor's preference and the patient's menstrual cycle regularity. * for artificially prepared transfers, estradiol hemihydrate (estrofem©, 2mg, novo nordisk, malov/denmark) 3x1 po will be started on the day 2 of the menstrual cycle. after 12-14 days of usage, in order not to cancel the cycle, endometrial thickness needs measured at least 7mm and serum progesterone level \< 1.5 ng/ml. * for luteal support in addition to progesterone (progestan dex©, 25mg, kocak farma i̇laç ve kimya sanayi a.ş., istanbul, turkiye) 2x1 sc once, with a 12-hour interval at day 14 of the menstrual cycle; progesterone (progestan©, 200mg, kocak farma i̇laç ve kimya sanayi a.ş., istanbul, turkiye) 2x1 pv will be started and continued for 5 days. embryo transfer will be performed at 6th day. estradiol hemihydrate will be stopped on week 2 and progesterone support will be continued until the 8th week of gestation.

Eligibility criteria:
inclusion criteria: * bmi \> 18 kg/m2 ve \<35 kg/m2 * couples that accept being included in the study * couple accepting thawed embryo transfer exclusion criteria: * known chromosomal abnormality in either member of the couple * couples with unexplained infertility * bmi \> 30 kg/m2 * mullerian malformations * undergoing oocyte cryopreservation for medical reasons (such as malignancies) * couple insists on fresh embryo transfer

Keywords: gnrh antagonist progestin primed ovarian stimulation infertility ovarian stimulation
emergence agitation in paediatric day care surgery

Conditions: Postoperative Delirium; Postoperative Agitation; Anesthesia; Pain Monitoring; Heart Rate Variability; Narcotrend; Mdoloris; Anesthesia Nociception Index

Summary: emergence agitation is a significant and persistent challenge in paediatric anaesthesia, especially in children of preschool age. in this study, the investigators examined whether anaesthesia titration with either a sleep depth monitor or a pain monitor would result in changed postoperative agitation rates, measured via the richmond agitation and sedation score (rass). 93 children participated. the participants were divided into three groups: a conventional anaesthesia group, an eeg (electroencephalography)- monitored and a pain-monitored group. the pain-monitored children received the most pain medication but were discharged at the same rate as the other children with unchanged rates of nausea and vomiting and less agitation than the sleep-monitored children.

healthy preschool outpatients assigned for abdominal/inguinal hernia and cryptorchidism repairs participated after parental consent. one group received standard anaesthesia induction and maintenance, according to the usual ward regimen. this was done with sevoflurane inhalation, fentanyl bolus and a laryngeal mask airway (standard group, std group) the second group received standard anaesthesia as well only this time the sevoflurane titration was guided via the nacotrend bispectral index monitor, towards a narcotrend index of 2-4. (narcotrend group, nct group) the third group also received standard anaesthesia and was additionally monitored with a mdoloris anaesthesia nociception index (ani) monitor for perioperative nociception. when a nociceptive threshold was exceeded, an extra bolus of fentanyl of 1 mcg/kg was given (ani group) all children were then escorted to the postoperative care unit for wakeup. a richmond agitation sedation scale score (rass-score) was made every 15 minutes until discharge. this was analysed with kaplan-meyer mortality graph, along with usual statistics of secondary outcomes. the children in the ani group received the least fentanyl and were discharged no later than all the other children.

Eligibility criteria:
inclusion criteria: * day surgery for abdominal and urological procedures * children 1-6 years * american society of anesthesiologist (asa) scale 1- 2 * airway management with laryngeal masks or facemasks * consent from both parents/legal representatives * rescue propofol is allowed exclusion criteria: * age less than 1 or older than 6 years * asa \> 2 * endotracheal intubation; * lack of consent from both parents/legal representatives * daily intake of medications that interfered with the autonomic nervous system reactivity, for example, inhaled beta-agonists for bronchial asthma and total intravenous anaesthesia (tiva).
virtual reality: a teaching-learning strategy for cognitive mastery in airway trauma management

Conditions: Education, Medical; Airway Management; Students, Medical; Virtual Reality; Trauma Centers; Manikins

Summary: airway injury in patients is a high risk and complex medical crisis. unfortunately, training for airway management in injured patients is challenging. the most effective way of practicing airway management is using mannequins. however, mannequin training is expensive and only occasionally available to medical trainees. the purpose of this study is to determine if virtual reality (vr) can be used to educate medical students on airway injury management. vr training will involve managing the care of a patient with an airway injury in an immersive, interactive vr hospital trauma bay. the investigators will compare the knowledge gained from vr training vs. mannequin training. the investigators will also investigate whether vr training teaches students faster than mannequin training. in addition, the investigators will identify factors which might affect learning from vr. medical students who choose to participate will be randomized (i.e. participant will have a 50% chance to be placed in either group) to be trained with vr or a mannequin. participants then will be trained on airway injury management using their assigned training approach. one week later, all participants will be assessed on their airway injury management skills using a mannequin. before and after their sessions, participants will also be asked to complete a questionnaire on their clinical decision-making. participants who received vr training will also complete a questionnaire about their experience with the vr training. this study will help develop a new approach to airway management training which is cheaper and more easily available to medical trainees than mannequin training. this educational tool could lead to better treatment of airway trauma in future patients.


Eligibility criteria:
inclusion criteria: * age ≥18 at time of consent * medical student at u of t in 1st, 2nd or 3rd year * able to attend two sessions a week apart exclusion criteria: * lack of participant consent or capacity to give consent * history of significant motion sickness (during exposure to physical, visual and virtual motion, cybersickness verbally declared by patient) * visual/hearing impairments that affect abilities to listen/watch videos/vr video
amino acid pet to assess the efficacy of idh inhibitor treatments for idh mutated gliomas

Conditions: Glioma

Summary: amino acid pet imaging could represent a biomarker for the evaluation of idh inhibitor treatments for patients with refractory idh-mutated gliomas

amino acid pet imaging could represent a biomarker for the evaluation of idh inhibitor treatments for patients with refractory idh-mutated gliomas in fact, this study will allow us to assess, using rano 1.0 criteria for pet and rano 2.0 criteria for mri, which of the two examinations is most effective in assessing the efficacy of anti-idh treatment patients with refractory idh-mutated gliomas.

Eligibility criteria:
inclusion criteria: * patients who underwent amino acid pet for early assessment of therapeutic response of idh-mutated gliomas under anti-idh treatment between february 2022 and november 2024 exclusion criteria: * individuals who have objected to the use of their data
saizen® e-device user trial

Conditions: Growth Disorders

Summary: the aim of the study is to evaluate the e-device performances and handling on the use in common practice, by collecting the impressions of patients, nurses and the investigator on the graphic interface, the instructions manual, the e-device training and the material itself.


Eligibility criteria:
inclusion criteria: 1. patients naïve to, or experienced with, saizen® with growth disorders in registered indications (ghd, turner's syndrome, chronic renal failure, patient born small gestational age \[sga\] according to the local smpc) 2. written informed consent must be obtained from the parent(s)/legal guardian(s) at the beginning of the study. children able to understand the trial should personally sign and date the written informed consent exclusion criteria: 1. known hypersensitivity to somatropin or any of the excipients 2. epiphyseal fusion 3. active neoplasia (either newly diagnosed or recurrent) 4. history of intracranial hypertension with papilledema 5. diabetes mellitus or history of significant glucose intolerance as defined by a fasting blood glucose \> 116 mg/dl 6. severe congenital malformations 7. severe psychomotor retardation 8. known hepatic disease as defined by elevated liver enzymes or total bilirubin (x 2 n) 9. current congestive heart failure, untreated hypertension, serious chronic oedema of any cause 10. chronic infectious disease 11. previous or ongoing treatment with sex steroid therapy such as estrogens and testosterone 12. previous or ongoing treatment with any therapy that may directly influence growth, including gh, ghrf and long duration corticosteroids therapy 13. proliferative or preproliferative diabetic retinopathy 14. evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion 15. precocious puberty 16. severe associated pathology affecting growth such as malnutrition, malabsorption or bone dysplasia 17. concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment 18. participation to any clinical study within the 30 days preceding study entry 19. pregnancy

Keywords: growth disorders
development and validation of family adjustment inventory

Conditions: Adjustment Reaction

Summary: a diagnosis of chronic disease in childhood may be disruptive for families. some parents show good adjustment, while others may have more difficulties. aim of this study is to develop and validate a new psychometric instrument to help precociously detect parents' vulnerability in the process of adjustment to their child's chronic disease at different times of care.

fai was developed in two different forms: 1. for parents with one children suffering from a chronic disease or ill children who has siblings younger than 3 years old - fai-o (only child); 2. for parents with at least two children, the brother/sister of the ill child has 3 years or more- fas-s (siblings) the two forms are identical, with the exception that fai-s has an additional dimension with respect to fai-o, that specifically regards the involvement of siblings in the illness path of the sick brother/sister. development of fai followed several steps: * definition of initial instrument dimensions * item wording for each dimension * definition of scoring * focus group with parents of patients suffering from a chronic disease to evaluate item content and linguistic clarity validation of fai for each form (fai-o and fai-s): validation consists in several steps, identical for the two versions but in different in timing, depending on the number of admnistration. * first phase: the fai is administered to parents of patients with different chronic disease (each form needs to reach the total of 300 administrations). * second phase: statistical analysis aimed to obtain the final version of each fai form (define actual dimensions and most adequate items) * third phase: administration to a new sample of parents of children suffering from a chronic disease (each form needs to reach the total of 150 administrations). * fourth phase: statistical analysis aimed to confirm the adequacy of the instrument

Eligibility criteria:
inclusion criteria: * consent for participating in the study * having a child suffering from a chronic illness and treated in the hospital in the following specialties: onco-hematology, neuro-oncology, diabetology, cystic fibrosis, metabolic disease, gastroenterology, cardiology, nephrology, rheumatology, allergology, pneumology, immunology, intensive care unit * italian speaking exclusion criteria: * cognitive impairment * no good knowledge of italian language

Keywords: adjustment family functioning chronic disease emotions
effect of plasmapheresis on clinical improvement and biological parameters of patients with long-haul covid

Conditions: Long-Haul COVID-19

Summary: many patients infected with sars-cov-2 present in the months following infection with non-specific symptoms such as non-resolving fatigue, cognitive disorders, dyspnea, headaches, myalgias, sleep disorders, anosmia/ ageusia and post exertion malaise. the persistence of these symptoms is called "post covid syndrome" or "long covid". according to the literature, the pathophysiological mechanisms involved in post-covid syndromes would include an inadequate immune response, activation of autoimmunity, persistence of pro-inflammatory biomarkers, endothelial dysfunction and alterations in the intestinal microbiota. in view of the involved pathophysiological mechanisms, linked to the circulation of pro-inflammatory molecules, autoimmunity or endothelial activation, the role of immuno-modulation in the treatment of long covid need to be evaluated. plasma exchange (pe) by decreasing blood levels of pro-inflammatory cytokines and/or autoimmune markers results in moderate to marked clinical improvement in various types of autoantibody-associated inflammatory, autoimmune and neurological diseases. the goal of our study is to evaluate the effects of plasmapheresis in patients with moderate to severe long-term covid compared to patients receiving no treatment.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years * who have had confirmed sars-cov2 infection (rt pcr) for at least 6 months * having for more than 6 months at least 3 symptoms among the following: fatigue, post effort malaise, dyspnea, headache, diffuse myalgia/arthromyalgia, neuropathic pain, cognitive disorders, anosmia/ageusia * whose above symptoms have an impact on daily activities * and/or on sick leave for more than 3 months * and/or having to take to bed for more than 2 hours a day * having given free and informed written consent * being affiliated with or benefiting from social security exclusion criteria: * with suspected covid-19 but not confirmed by rt-pcr test * having a known history of any other pathology that could be confused with the diagnosis of long covid: multiple sclerosis, autoimmune disease (lupus and gougerot syndrome, inflammatory muscle disease, and myasthenia gravis), untreated hypothyroidism, major depression, use of narcotics regular. * unable to perform a cycle ergometer stress test * with innate or drug-induced coagulation disorders (oral or parenteral anticoagulation) * with contraindications to plasmapheresis such as: lack of peripheral venous access or unstable cardiac pathology * pregnant or breastfeeding woman
the effect of the use of sterile transparent film dressing in newborns

Conditions: Newborn; Peripheral Venous Catheterization

Summary: it is important that effective catheter fixation will reduce the risk of catheter unavailability for specific reasons and the incidence of catheter-related complications. the aim of this study was to determine the effect of sterile transparent film dressing and tape methods used in pe- ripheral intravenous catheter application in newborns on the duration of catheter stay and the development of catheter-related complications.

it has been reported that effective catheter fixation will reduce the risk of catheter unavailability for specific reasons and the incidence of catheter-related complications. intravenous cannulas are usually fixed with a thin board, a bandage, and tape. there is no standard way of using pivc dressings in turkey. after the catheter is inserted into the vein, gauze and a blaster, sterile transparent dressing materials, or just a blaster, are used to prevent contact of the fixed part and the area of intervention with the external environment. transparent dressing used for catheter fixation contribute to a more comfortable evaluation of the catheter entry site. it has been suggested that the use of transparent film dressing may be effective in preventing and early detection of catheter-related complications. moreover, it was concluded that due to the short duration of the procedure, it reduced the cost of manpower, and nurses could devote more time to other patients.

Eligibility criteria:
inclusion criteria: * less than 4 kg (due to the infiltration scale criteria) * picv was inserted for the first time exclusion criteria: * existing catheter, * who has a catheter other than picv (picc, umbilical catheter, etc.), * sterile transparent film dressing, tape, babies with allergies to antiseptic solution and catheter, * with immunodeficiency, and with skin problems that prevent catheter opening